{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:19:08Z","timestamp":1778541548679,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,3,8]],"date-time":"2006-03-08T00:00:00Z","timestamp":1141776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Veterinary Medicine Series A"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This trial's aim was to evaluate the effect of in\u2010feed lincomycin for the control of proliferative enteropathy (PE; also known as ileitis) in growing pigs, in which it is associated with significant morbidity levels. Investigation regarding the efficacy of this substance in growing pigs has never been carried out before in a field trial. The trial farm had a previous history of PE outbreaks. On day 1 of the trial (age of 62\u2003\u00b1\u20031.5\u2003days), 240 pigs were divided into two groups of 120 pigs\/group which were allocated into five pens of 24 pigs each. Therefore, a randomized block design was used with two experimental groups (T1\u2013T2) and five replicates (pens) per group. T1 group served as negative control (NC) animals which were receiving no medication and conversely T2 group received in\u2010feed lincomycin at the dose of 110\u2003mg\/kg of feed. The treatment period lasted for 3\u2003weeks, followed by an observation period of 4\u2003weeks up to the age of 111\u2003\u00b1\u20031.5\u2003days which was the end of the grower stage. Administration of lincomycin at a dose of 110\u2003mg\/kg of feed had beneficial effects compared with the NC group. The pigs of T2 group showed significant improvement of their production parameters in terms of average daily body gain (ADG) and feed conversion ratio (FCR) not only during the treatment period (ADG: 0.515\u2003\u00b1\u20030.050 versus 0.481\u2003\u00b1\u20030.071 and FCR: 2.38\u2003\u00b1\u20030.05 versus 2.56\u2003\u00b1\u20030.08, for T2 and T1 groups respectively), but also during the remaining period until the end of the grower stage (observation period: ADG: 0.687\u2003\u00b1\u20030.019 versus 0.646\u2003\u00b1\u20030.044 and FCR: 2.58\u2003\u00b1\u20030.02 versus 2.74\u2003\u00b1\u20030.02 respectively). Other effects in the T2 group refer to the reduction of diarrhoea prevalence (mean pen diarrhoea score during the whole grower stage: 0.200\u2003\u00b1\u20030.060 versus 0.632\u2003\u00b1\u20030.041 respectively), morbidity rates (morbidity rates during the whole grower stage: 15.83% versus 45.00% respectively) and the reduction of<jats:italic>Lawsonia intracellularis<\/jats:italic>prevalence as shown by polymerase chain reaction diagnostic method (at the end of the treatment period: 10.0% versus 60.0% respectively). In conclusion, treatment with 110\u2003mg lincomycin\/kg of feed for 21 consecutive days had a beneficial effect on the control of PE in growing pigs.<\/jats:p>","DOI":"10.1111\/j.1439-0442.2006.00803.x","type":"journal-article","created":{"date-parts":[[2006,3,8]],"date-time":"2006-03-08T13:02:35Z","timestamp":1141822955000},"page":"157-162","source":"Crossref","is-referenced-by-count":8,"title":["First Experience on the Effect of In\u2010feed Lincomycin for the Control of Proliferative Enteropathy in Growing Pigs"],"prefix":"10.1111","volume":"53","author":[{"given":"C.","family":"Alexopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. D.","family":"Tassis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. S.","family":"Kyriakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. D.","family":"Tzika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Papatsiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. C.","family":"Kyriakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,3,8]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"155","article-title":"Porcine proliferative enteropathy: a case\u2010control study in swine herds in the United States","volume":"9","author":"Bane D. P.","year":"2001","journal-title":"J. Sw. Health Prod."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.28.3.495-503.1990"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1135(96)01264-3"},{"key":"e_1_2_6_5_1","first-page":"4","volume-title":"Code of Good Veterinary Practice (GVP Code)","author":"Federation of Veterinarians of Europe (FVE)","year":"2001"},{"key":"e_1_2_6_6_1","first-page":"1","volume-title":"Lincomycin Feed Medications for the Control of Porcine Proliferative Enteropathies (ileitis) Caused by Lawsonia intracellularis.","author":"Food and Drug Administration (FDA)","year":"2002"},{"key":"e_1_2_6_7_1","volume-title":"Direct In Vitro Testing of Antimicrobial Agents for the Proliferative Enteropathy. Research Investment Report","author":"Gebhart C. J.","year":"1995"},{"key":"e_1_2_6_8_1","first-page":"736","volume-title":"Current Veterinary Therapy Food Animal Practice","author":"Glock R. D.","year":"1981"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.1991.tb03114.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1128\/jcm.31.10.2611-2615.1993","article-title":"Enhanced detection of intracellular organism of swine proliferative enteritis, ileal symbiont intracellularis, in faeces by polymerase chain reaction","volume":"31","author":"Jones G. F.","year":"1993","journal-title":"J. Clin. Microbiol."},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2460\/ajvr.1998.59.06.722","article-title":"Evaluation of antemortem polymerase chain reaction and serologic methods for detection of L. intracellularis\u2010exposed pigs","volume":"59","author":"Knittel J. P.","year":"1998","journal-title":"Am. J. Vet. Res."},{"key":"e_1_2_6_12_1","first-page":"24","volume-title":"Proceedings of the 16th International Pig Veterinary Society Congress, Melbourne, Australia","author":"Knittel J. P.","year":"2000"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.138.20.489"},{"key":"e_1_2_6_14_1","first-page":"521","volume-title":"Diseases of Swine","author":"McOrist S.","year":"1999"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1135(94)90101-5"},{"key":"e_1_2_6_16_1","first-page":"1136","article-title":"Characterization of Lawsonia intracellularis gen. nov. sp. nov., the obligatory intracellular bacterium of porcine proliferative enteropathy","volume":"33","author":"McOrist S.","year":"1995","journal-title":"Int. J. Syst. Bacteriol."},{"key":"e_1_2_6_17_1","first-page":"615","article-title":"Treatment and prevention of porcine proliferative enteropathy with oral tiamulin","volume":"139","author":"McOrist S.","year":"1996","journal-title":"Vet. Rec."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.140.22.579"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2460\/ajvr.1997.58.02.136","article-title":"Oral administration of tylosin phosphate for the treatment and prevention of proliferative enteropathy in pigs","volume":"58","author":"McOrist S.","year":"1997","journal-title":"Am. J. Vet. Res."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.146.3.61"},{"key":"e_1_2_6_21_1","first-page":"1782","volume-title":"Merck Veterinary Manual","author":"Merck","year":"1998"},{"key":"e_1_2_6_22_1","first-page":"2","volume-title":"Series on Principles of Good Laboratory Practice (GLP) and Compliance Monitoring","author":"Organization for Economic Co\u2010operation and Development (OECD)","year":"1998"},{"key":"e_1_2_6_23_1","first-page":"882","volume-title":"Veterinary Pharmacology and Therapeutics","author":"Papich M. G.","year":"2001"},{"key":"e_1_2_6_24_1","first-page":"615","volume-title":"Clinical Veterinary Microbiology, Appendix 1","author":"Quinn P. J.","year":"1994"},{"key":"e_1_2_6_25_1","first-page":"521","volume-title":"Diseases of Swine","author":"Rowland A. C.","year":"1992"},{"key":"e_1_2_6_26_1","first-page":"154","volume-title":"Pig Diseases","author":"Taylor D. J.","year":"1995"},{"key":"e_1_2_6_27_1","first-page":"6","volume-title":"Guidelines on Statistical Principles for Veterinary Clinical Trials","author":"The European Agency for the Evaluation of Medicinal Products, Veterinary Medicines and Inspections, EMEA CVMP 816\/00","year":"2001"},{"key":"e_1_2_6_28_1","first-page":"1","volume-title":"VICH Topic GL9 (GCP) Step 4 Guideline on Good Clinical Practices","author":"The European Agency for the Evaluation of Medicinal Products, Veterinary Medicines Evaluation Unit, EMEA CVMP 595","year":"1998"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0450.1998.tb00773.x"},{"key":"e_1_2_6_30_1","first-page":"64","volume-title":"Proceedings of the 15th International Pig Veterinary Society Congress, Birmingham, UK","author":"Veenhuizen M. F.","year":"1998"},{"key":"e_1_2_6_31_1","first-page":"107","article-title":"Lincomycin\u2010medicated feed for the control of porcine proliferative enteropathy (ileitis) in swine","volume":"10","author":"Winkelman N. L.","year":"2002","journal-title":"J. Sw. Health Prod."},{"key":"e_1_2_6_32_1","first-page":"248","article-title":"A reliable method for the demonstration of spirochetes in tissue sections","volume":"26","author":"Young B. J.","year":"1969","journal-title":"J. Med. Lab. Technol."}],"container-title":["Journal of Veterinary Medicine Series A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0442.2006.00803.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0442.2006.00803.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T07:07:34Z","timestamp":1706944054000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0442.2006.00803.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,8]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1111\/j.1439-0442.2006.00803.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0442.2006.00803.x","archive":["Portico"],"relation":{},"ISSN":["0931-184X"],"issn-type":[{"value":"0931-184X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3,8]]}}}